The Probiotic Strain H. alvei HA4597® Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study
| Autor: | Gregory Lambert, Barbara Grube, Clémentine Trotin-Picolo, Gordana Bothe, Constantin Erlenbeck, Pierre Déchelotte, Jonathan Breton, Sergueï O. Fetissov |
|---|---|
| Přispěvatelé: | Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de nutrition [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), TargEDys SA, Practice for General Medicine, Analyze & Realize GmbH, Inserm UMR 1239, Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Neuroendocrine, Endocrine and Germinal Differentiation Communication (NorDic), douville, sabine |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Placebo-controlled study Overweight Gastroenterology law.invention 0302 clinical medicine Randomized controlled trial Weight loss law Clinical endpoint TX341-641 Prospective Studies Nutrition and Dietetics Middle Aged 3. Good health appetite Female medicine.symptom overweight subjects Adult medicine.medical_specialty Adolescent Diet Reducing HA4597® 030209 endocrinology & metabolism H. alvei HA4597 Placebo Statistics Nonparametric Article Young Adult 03 medical and health sciences Double-Blind Method Internal medicine Weight Loss medicine Humans Obesity Exercise Aged hip circumference gut microbiota Nutrition. Foods and food supply business.industry Body Weight Hafnia alvei medicine.disease Gastrointestinal Microbiome feeling of fullness [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition 030104 developmental biology probiotics Anti-Obesity Agents business Weight gain [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition Food Science |
| Zdroj: | Nutrients Nutrients, MDPI, 2021, 13 (6), pp.1902. ⟨10.3390/nu13061902⟩ Nutrients, 2021, 13 (6), pp.1902. ⟨10.3390/nu13061902⟩ Volume 13 Issue 6 Nutrients, Vol 13, Iss 1902, p 1902 (2021) |
| ISSN: | 2072-6643 |
| DOI: | 10.3390/nu13061902⟩ |
| Popis: | Background: Increasing evidence supports the role of the gut microbiota in the control of body weight and feeding behavior. Moreover, recent studies have reported that the probiotic strain Hafnia alvei HA4597® (HA), which produces the satietogenic peptide ClpB mimicking the effect of alpha-MSH, reduced weight gain and adiposity in rodent models of obesity. Methods: To investigate the clinical efficacy of HA, 236 overweight subjects were included, after written informed consent, in a 12-week prospective, double-blind, randomized study. All subjects received standardized counselling for a −20% hypocaloric diet and were asked to maintain their usual physical activity. Subjects of the HA group received two capsules per day providing 100 billion bacteria per day and subjects in the Placebo (P) group received two placebo capsules. The primary endpoint was the percentage of subjects achieving a weight loss of at least 3% after 12 weeks. Intention-to-treat statistical analysis was performed using exact-Fischer, Mann-Whitney and paired-Wilcoxon tests as appropriate. Results: In the HA group, significantly more subjects (+33%) met the primary endpoint than in the P group (54.9 vs. 41.4%, p = 0.048). In the HA group, an increased feeling of fullness (p = 0.009) and a greater loss of hip circumference (p < 0.001) at 12 weeks were also observed. Fasting glycemia at 12 weeks was significantly lower (p < 0.05) in the HA compared to P group. Clinical and biological tolerance was good in both groups. Conclusions: A 12-week treatment with the probiotic strain H. alvei HA4597® significantly improves weight loss, feeling of fullness and reduction of hip circumference in overweight subjects following moderate hypocaloric diet. These data support the use of H. alvei HA4597® in the global management of excess weight. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|